https://www.selleckchem.com/pr....oducts/sitravatinib-
nificant difference between the intervention arms in the primary outcome (odds ratio [OR], 1.14; 95% CI, 0.77-1.7; P = .51), but each intervention arm had significantly lower odds of type 2 diabetes (INT OR, 0.54; 95% CI, 0.34-0.85; P = .01; INT-DPM OR, 0.61; 95% CI, 0.39-0.96; P = .033; combined OR, 0.57; 95% CI, 0.38-0.87; P = .01). The effect size was similar in all glycemic, age, and social deprivation groups, and intervention costs per participant were low at $153 (£122). The Norfolk Diabetes Prevention lifestyle inter
Like
Comment
Share
